Cat. No. | Product name | CAS No. |
DCE-016 |
Chenodeoxycholic acid
>98%,Standard References |
474-25-9 |
DC11547 |
LY-2562175
Featured
LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM. |
1103500-20-4 |
DC10868 |
Cilofexor
Featured
Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models. |
1418274-28-8 |
DC8069 |
Fexaramate
Featured
Fexaramate is a potent, selective farnesoid X receptor agonist. |
592524-75-9 |
DC8085 |
Fexaramine
Featured
Fexaramine is a potent, selective FXR activator. |
574013-66-4 |
DC8070 |
Fexarene
Featured
Fexarene is a potent, selective farnesoid X receptor agonist. |
574013-68-6 |
DC8071 |
Fexarine
Featured
Fexarine is a potent, selective farnesoid X receptor agonist. |
574013-67-5 |
DC7566 |
GW-4064
Featured
GW 4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM). |
278779-30-9 |
DC7430 |
Obeticholic acid (INT-747)
Featured
INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity. |
459789-99-2 |
DC10470 |
SB756050
Featured
SB-756050 is a Farnesoid X receptor (FXR) (NR1H4) agonist. |
447410-57-3 |
DC10737 |
Tropifexor (LJN452)
Featured
Tropifexor (LJN452) is a highly potent non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). |
1383816-29-2 |
DC7040 |
WAY-362450 (XL335; Turofexorate isopropyl)
Featured
WAY-362450 (XL335; Turofexorate isopropyl) is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist with an EC50 of 4 nM.WAY-362450 is useful for dyslipidemia. |
629664-81-9 |
DC28475 |
NR1H4 activator 1
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease. |
2242855-68-9 |
DC28850 |
Tauro-Obeticholic acid
Tauro-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist. |
863239-61-6 |
DC28851 |
Glyco-Obeticholic acid
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist. |
863239-60-5 |
DC46688 |
Sevelamer-(d5)n hydrochloride
Sevelamer-(d5)n hydrochloride is the deuterium labeled Sevelamer hydrochloride. Sevelamer hydrochloride is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin. |
|
DC47987 |
FXR/TGR5 agonist 1
FXR/TGR5 agonist 1 has agonist action on FXR and TGR5, and can be used for the treatment of fatty liver disease. |
2677689-72-2 |
DC50221 |
NDB
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research. |
1660153-08-1 |
DC50222 |
BMS-986318
BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis. |
2314378-09-9 |
DC50223 |
Chenodeoxycholic acid-d5
Chenodeoxycholic acid-d5 (CDCA-d5) is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
52840-12-7 |
DC50224 |
Chenodeoxycholic acid-13C
Chenodeoxycholic acid-13C (CDCA-13C) is the 13C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
52918-92-0 |
DC70074 |
GSK-2324
GSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay. |
1020567-30-9 |